Double-Drug attack on lung cancer: can two targeted pills work better than one?
NCT ID NCT03122717
First seen Nov 12, 2025 · Last updated May 01, 2026 · Updated 24 times
Summary
This study tests whether combining two targeted drugs, osimertinib and gefitinib, is safe and doable for people with advanced EGFR-mutant lung cancer. About 48 adults with stage IV non-small cell lung cancer that has not been treated with EGFR inhibitors before will take both pills daily for up to 6 months. The main goal is to see how many can stay on the combo without stopping due to side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.